Literature DB >> 30373797

In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Safa S Almarzoky Abuhussain1,2, Lindsay M Avery1, Kamilia Abdelraouf1, David P Nicolau3,4.   

Abstract

Herein, we describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against carbapenem-resistant Acinetobacter baumannii strains in a neutropenic murine thigh infection model. Five of the six isolates examined expressed OXA-23 or OXA-24. WCK 5222, despite showing MICs of 16 to 64 mg/liter, produced remarkable in vivo activity; human-simulated exposure showed a decline in the bacterial burden for all isolates (mean reduction, -2.09 ± 1.01 log10 CFU/thigh), while a lack of activity was observed with cefepime and zidebactam monotherapies.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  human simulated; pharmacodynamics; pharmacokinetics

Mesh：

Substances：

Year:  2018        PMID： 30373797      PMCID： PMC6325183          DOI： 10.1128/AAC.01931-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Anna Vickers; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

2.  Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

3.  Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia.

Authors:  Li-Yang Hsu; Anucha Apisarnthanarak; Erum Khan; Nuntra Suwantarat; Abdul Ghafur; Paul Anantharajah Tambyah
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

5.  Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Anasuya Patel; Rajesh Chavan; Ravindra Yeole; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.

Authors:  Akihiro Morinaka; Yuko Tsutsumi; Mototsugu Yamada; Kenji Suzuki; Takashi Watanabe; Takao Abe; Takeshi Furuuchi; Seiichi Inamura; Yoshiaki Sakamaki; Nakako Mitsuhashi; Takashi Ida; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2015-06-18       Impact factor: 5.790

Review 7.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

8.  Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Authors:  Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 9.  Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.

Authors:  Sirijan Santajit; Nitaya Indrawattana
Journal:  Biomed Res Int       Date:  2016-05-05       Impact factor: 3.411

Review 10.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293
View more
  11 in total

1.  In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Jennifer Tabor-Rennie; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 2.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

Review 3.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

4.  In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018.

Authors:  Yang Yang; Yan Guo; Dandan Yin; Yonggui Zheng; Shi Wu; Demei Zhu; Fupin Hu
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

5.  WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 6.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 7.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

8.  In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.

Authors:  Matthew Gethers; Iris Chen; Kamilia Abdelraouf; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758

9.  In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China.

Authors:  Renru Han; Li Ding; Yang Yang; Yan Guo; Dandan Yin; Shi Wu; Peiyuan Zhi; Demei Zhu; Qingmei Liu; Xiaojuan Tan; Yuanju Zhu; Jay Zhang; Li Li; Fupin Hu
Journal:  Microbiol Spectr       Date:  2022-02-09

Review 10.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.